SRDX vs. SIBN, ANIK, XENT, ATEC, ATRC, OFIX, ANGO, ARAY, RMTI, and RSLS
Should you be buying Surmodics stock or one of its competitors? The main competitors of Surmodics include SI-BONE (SIBN), Anika Therapeutics (ANIK), Intersect ENT (XENT), Alphatec (ATEC), AtriCure (ATRC), Orthofix Medical (OFIX), AngioDynamics (ANGO), Accuray (ARAY), Rockwell Medical (RMTI), and ReShape Lifesciences (RSLS). These companies are all part of the "medical" sector.
Surmodics (NASDAQ:SRDX) and SI-BONE (NASDAQ:SIBN) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, community ranking, profitability, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and risk.
In the previous week, Surmodics and Surmodics both had 5 articles in the media. SI-BONE's average media sentiment score of 0.93 beat Surmodics' score of 0.75 indicating that SI-BONE is being referred to more favorably in the news media.
Surmodics received 176 more outperform votes than SI-BONE when rated by MarketBeat users. However, 67.36% of users gave SI-BONE an outperform vote while only 65.56% of users gave Surmodics an outperform vote.
Surmodics presently has a consensus price target of $50.00, indicating a potential upside of 20.66%. SI-BONE has a consensus price target of $25.67, indicating a potential upside of 58.83%. Given SI-BONE's stronger consensus rating and higher possible upside, analysts plainly believe SI-BONE is more favorable than Surmodics.
96.6% of Surmodics shares are owned by institutional investors. Comparatively, 98.1% of SI-BONE shares are owned by institutional investors. 8.9% of Surmodics shares are owned by company insiders. Comparatively, 5.4% of SI-BONE shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Surmodics has a beta of 1.18, suggesting that its stock price is 18% more volatile than the S&P 500. Comparatively, SI-BONE has a beta of 1.2, suggesting that its stock price is 20% more volatile than the S&P 500.
Surmodics has a net margin of 9.44% compared to SI-BONE's net margin of -29.93%. Surmodics' return on equity of 13.30% beat SI-BONE's return on equity.
Surmodics has higher revenue and earnings than SI-BONE. SI-BONE is trading at a lower price-to-earnings ratio than Surmodics, indicating that it is currently the more affordable of the two stocks.
Summary
Surmodics beats SI-BONE on 9 of the 17 factors compared between the two stocks.
Get Surmodics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SRDX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SRDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Surmodics Competitors List
Related Companies and Tools
Free SRDX Stock Alerts